Comparison of the diagnostic value of 68Ga-FAPI and 18F-FDG PET/CT in breast cancer: a systematic review

IF 2.3 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Jiayu Zhang, Jie Xiong, Min Wang, Bin Wu, Chunyin Zhang
{"title":"Comparison of the diagnostic value of 68Ga-FAPI and 18F-FDG PET/CT in breast cancer: a systematic review","authors":"Jiayu Zhang, Jie Xiong, Min Wang, Bin Wu, Chunyin Zhang","doi":"10.1007/s40336-024-00656-x","DOIUrl":null,"url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>Although <sup>18</sup>F-FDG PET/CT is helpful in detecting primary breast cancer and its distant metastases, <sup>68</sup>Ga-FAPI PET/CT may perform better in detecting primary breast cancers at an earlier stage and metastatic lesions (lymph node, etc.). This study aimed to systematically review the diagnostic value of <sup>68</sup>Ga-FAPI PET/CT versus <sup>18</sup>F-FDG PET/CT in terms of diagnostic accuracy parameters (sensitivity, specificity) and quantitative parameters (SUVmax, TBR, etc.) for the diagnosis of primary and metastatic lesions of breast cancer.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This study followed the PRISMA guidelines for systematic reviews. A comprehensive search of the PubMed, EMBASE and Web of Science databases was performed to identify studies that met the eligibility criteria from 2000–01 to 2023–07. The quality of the relevant studies with the QUADAS-2 method was assessed via ReviewManager v.5 software. The literature included female breast cancer patients with the pathologic type of invasive carcinoma who had received both <sup>18</sup>F-FDG and <sup>68</sup>Ga-FAPI PET/CT.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 238 documents were retrieved, and 6 were ultimately included. The results revealed that <sup>68</sup>Ga-FAPI PET/CT had a greater SUVmax, TBR, and sensitivity than FDG did.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>In this study, we compared the value of <sup>68</sup>Ga-FAPI PET/CT and <sup>18</sup>F-FDG PET/CT in breast cancer patients. For both primary and metastatic foci of breast cancer, <sup>68</sup>Ga-FAPI PET/CT resulted in a higher lesion detection rate and tracer uptake. Second, <sup>68</sup>Ga-FAPI PET/CT can improve patient staging and provide some prognostic information, including the pathological response. In addition, <sup>68</sup>Ga-FAPI PET/CT imaging can detect additional lesions as a complementary tool.</p><h3 data-test=\"abstract-sub-heading\">Systematic review registration</h3><p>https://www.crd.york.ac.uk/PROSPERO/, identifier (CRD42023491138).</p>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40336-024-00656-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Although 18F-FDG PET/CT is helpful in detecting primary breast cancer and its distant metastases, 68Ga-FAPI PET/CT may perform better in detecting primary breast cancers at an earlier stage and metastatic lesions (lymph node, etc.). This study aimed to systematically review the diagnostic value of 68Ga-FAPI PET/CT versus 18F-FDG PET/CT in terms of diagnostic accuracy parameters (sensitivity, specificity) and quantitative parameters (SUVmax, TBR, etc.) for the diagnosis of primary and metastatic lesions of breast cancer.

Methods

This study followed the PRISMA guidelines for systematic reviews. A comprehensive search of the PubMed, EMBASE and Web of Science databases was performed to identify studies that met the eligibility criteria from 2000–01 to 2023–07. The quality of the relevant studies with the QUADAS-2 method was assessed via ReviewManager v.5 software. The literature included female breast cancer patients with the pathologic type of invasive carcinoma who had received both 18F-FDG and 68Ga-FAPI PET/CT.

Results

A total of 238 documents were retrieved, and 6 were ultimately included. The results revealed that 68Ga-FAPI PET/CT had a greater SUVmax, TBR, and sensitivity than FDG did.

Conclusion

In this study, we compared the value of 68Ga-FAPI PET/CT and 18F-FDG PET/CT in breast cancer patients. For both primary and metastatic foci of breast cancer, 68Ga-FAPI PET/CT resulted in a higher lesion detection rate and tracer uptake. Second, 68Ga-FAPI PET/CT can improve patient staging and provide some prognostic information, including the pathological response. In addition, 68Ga-FAPI PET/CT imaging can detect additional lesions as a complementary tool.

Systematic review registration

https://www.crd.york.ac.uk/PROSPERO/, identifier (CRD42023491138).

Abstract Image

68Ga-FAPI 和 18F-FDG PET/CT 对乳腺癌诊断价值的比较:系统性综述
尽管18F-FDG PET/CT有助于检测原发性乳腺癌及其远处转移,但68Ga-FAPI PET/CT在检测早期原发性乳腺癌和转移病灶(淋巴结等)方面可能表现更好。本研究旨在系统回顾 68Ga-FAPI PET/CT 与 18F-FDG PET/CT 在诊断乳腺癌原发和转移病灶的诊断准确性参数(灵敏度、特异性)和定量参数(SUVmax、TBR 等)方面的诊断价值。对 PubMed、EMBASE 和 Web of Science 数据库进行了全面检索,以确定 2000-01 年至 2023-07 年期间符合资格标准的研究。通过ReviewManager v.5软件,采用QUADAS-2方法对相关研究的质量进行了评估。文献包括同时接受 18F-FDG 和 68Ga-FAPI PET/CT 的病理类型为浸润癌的女性乳腺癌患者。结果共检索到 238 篇文献,最终纳入 6 篇。结果显示,68Ga-FAPI PET/CT 的 SUVmax、TBR 和灵敏度均高于 FDG。对于乳腺癌的原发灶和转移灶,68Ga-FAPI PET/CT 的病灶检出率和示踪剂摄取率都更高。其次,68Ga-FAPI PET/CT 可以改善患者的分期,并提供一些预后信息,包括病理反应。此外,68Ga-FAPI PET/CT成像作为一种补充工具,还能发现其他病变。系统综述注册https://www.crd.york.ac.uk/PROSPERO/,标识符(CRD42023491138)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical and Translational Imaging
Clinical and Translational Imaging Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
3.60
自引率
4.80%
发文量
55
期刊介绍: Clinical and Translational Imaging is an international journal that publishes timely, up-to-date summaries on clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes. Coverage includes such topics as advanced preclinical evidence in the fields of physics, dosimetry, radiation biology and radiopharmacy with relevance to applications in human subjects. The journal benefits a readership of nuclear medicine practitioners and allied professionals involved in molecular imaging and therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信